Active-site directed probes to report enzymatic action in the ubiquitin proteasome system

Nature Reviews Cancer

Volumn 7, Issue 8, 2007, Pages 613-620

  Ovaa, Huib ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; LDN 57444; PROTEASOME; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

BIOINFORMATICS; CANCER CHEMOTHERAPY; CATALYSIS; CHLAMYDIA; CROSS REACTION; CYTOMEGALOVIRUS; DNA REPAIR; ENZYME ACTIVITY; ESCHERICHIA COLI; MOLECULAR IMAGING; MOLECULAR PROBE; NONHUMAN; PLASMODIUM FALCIPARUM; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; REVIEW; UBIQUITINATION;

ANIMALS; BINDING SITES; DRUG DESIGN; MOLECULAR PROBES; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 34547093612     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2128     Document Type: Review

References (130)

1. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
2. Glickman, M. H. & Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373-428 (2002).
3. Akiyama, K. et al. Replacement of proteasome subunits X and Y by LMP7 and LMP2 induced by interferon-γ for acquirement of the functional diversity responsible for antigen processing. FEBS Lett. 343, 85-88 (1994).
4. + T cell development by thymus-specific proteasomes. Science 316, 1349-1353 (2007).
5. Nalepa, G., Rolfe, M. & Harper, J. W. Drug discovery in the ubiquitin-proteasome system. Nature Rev. Drug Discov. 5, 596-613 (2006).
6. Chauhan, D. et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8, 407-419 (2005).
7. Raiborg, C., Slagsvold, T. & Stenmark, H. A new side to ubiquitin. Trends Biochem. Sci. 31, 541-544 (2006).
8. Hicke, L. Protein regulation by monoubiquitin. Nature Rev. Mol. Cell Biol. 2, 195-201 (2001).
9. Li, W., Tu, D., Brunger, A. T. & Ye, Y. A ubiquitin ligase transfers preformed polyubiquitin chains from a conjugating enzyme to a substrate. Nature 446, 333-337 (2007).
10. Haglund, K. & Dikic, I. Ubiquitylation and cell signaling. EMBO J. 24, 3353-3359 (2005).
11. Pickart, C. M. & Eddins, M. J. Ubiquitin: structures, functions, mechanisms. Biochim. Biophys. Acta 1695, 55-72 (2004).
12. Pickart, C. M. Back to the future with ubiquitin. Cell 116, 181-190 (2004).
13. Brondani, V., Schefer, Q., Hamy, F. & Klimkait, T. The peptidyl-prolyl isomerase Pin1 regulates phospho-Ser77 retinoic acid receptor alpha stability. Biochem. Biophys. Res. Commun. 328, 6-13 (2005).
14. Nijman, S. M. et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773-786 (2005).
15. Crosas, B. et al. Ubiquitin chains are remodeled at the proteasome by opposing ubiquitin ligase and deubiquitinating activities. Cell 127, 1401-1413 (2006).
16. Hemelaar, J. et al. Chemistry-based functional proteomics: mechanism-based activity-profiling tools for ubiquitin and ubiquitin-like specific proteases. J. Proteome Res. 3, 268-276 (2004).
17. Zhou, H. et al. Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-κ B activation. J. Exp. Med. 202, 1327-1332 (2005).
18. Wada, H., Kito, K., Caskey, L. S., Yeh, E. T. & Kamitani, T. Cleavage of the C-terminus of NEDD8 by UCH-L3. Biochem. Biophys. Res. Commun. 251, 688-692 (1998).
19. Wu, K. et al. DEN1 is a dual function protease capable of processing the C terminus of Nedd8 and deconjugating hyper-neddylated CUL1. J. Biol. Chem. 278, 28882-28891 (2003).
20. Gan-Erdene, T. et al. Identification and characterization of DEN1, a deneddylase of the ULP family. J. Biol. Chem. 278, 28892-28900 (2003).
21. Nakayama, K. I. & Nakayama, K. Ubiquitin ligases: cell-cycle control and cancer. Nature Rev. Cancer 6, 369-381 (2006).
22. Hoeller, D., Hecker, C. M. & Dikic, I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nature Rev. Cancer 6, 776-788 (2006).
23. Dantuma, N. P., Lindsten, K., Glas, R., Jellne, M. & Masucci, M. G. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome- dependent proteolysis in living cells. Nature Biotechnol. 18, 538-543 (2000).
24. Groothuis, T. A., Dantuma, N. P., Neefjes, J. & Salomons, F. A. Ubiquitin crosstalk connecting cellular processes. Cell Div. 1, 21 (2006).
25. Dantuma, N. P., Groothuis, T. A., Salomons, F. A. & Neefjes, J. A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling. J. Cell Biol. 173, 19-26 (2006).
26. Yao, T. & Cohen, R. E. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature 419, 403-407 (2002).
27. Lindsten, K., Menendez-Benito, V., Masucci, M. G. & Dantuma, N. P. A transgenic mouse model of the ubiquitin/proteasome system. Nature Biotechnol. 21, 897-902 (2003).
28. Luker, G. D., Pica, C. M., Song, J., Luker, K. E. & Piwnica-Worms, D. Imaging 26S proteasome activity and inhibition in living mice. Nature Med. 9, 969-973 (2003).
29. Evans, M. J. & Cravatt, B. F. Mechanism-based profiling of enzyme families. Chem. Rev. 106, 3279-3301 (2006).
30. van Swieten, P. F., Leeuwenburgh, M. A., Kessler, B. M. & Overkleeft, H. S. Bioorthogonal organic chemistry in living cells: novel strategies for labeling biomolecules. Org. Biomol. Chem. 3, 20-27 (2005).
31. Sadaghiani, A. M., Verhelst, S. H. & Bogyo, M. Tagging and detection strategies for activity-based proteomics. Curr. Opin. Chem. Biol. 11, 20-28 (2007).
32. Harris, J. L., Alper, P. B., Li, J., Rechsteiner, M. & Backes, B. J. Substrate specificity of the human proteasome. Chem. Biol. 8, 1131-1141 (2001).
33. Fenteany, G., Standaert, R. F., Reichard, G. A., Corey, E. J. & Schreiber, S. L. A β-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc. Natl Acad. Sci. USA 91, 3358-3362 (1994).
34. Fenteany, G. et al. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268, 726-731 (1995).
35. Bogyo, M., Shin, S., McMaster, J. S. & Ploegh, H. L. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem. Biol. 5, 307-320 (1998).
36. Bogyo, M. et al. Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc. Natl Acad. Sci. USA 94, 6629-6634 (1997).
37. Kessler, B. M. et al. Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits. Chem. Biol. 8, 913-929 (2001).
38. Kim, K. B., Myung, J., Sin, N. & Crews, C. M. Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg. Med. Chem. Lett. 9, 3335-3340 (1999).
39. Sin, N. et al. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg. Med. Chem. Lett. 9, 2283-2288 (1999).
40. Ovaa, H. et al. Chemistry in living cells: detection of active proteasomes by a two-step labeling strategy. Angew. Chem. Int. Ed. Engl. 42, 3626-3629 (2003).
41. van Swieten, P. F. et al. A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome. Bioorg. Med. Chem. Lett. 17, 3402-3405 (2007).
42. Berkers, C. R. et al. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nature Methods 2, 357-362 (2005).
43. Kristiansen, M. et al. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol. Cell 26, 175-188 (2007).
44. Ho, Y. K., Bargagna-Mohan, P., Wehenkel, M., Mohan, R. & Kim, K. B. LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem. Biol. 14, 419-430 (2007).
45. Verdoes, M. et al. A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem. Biol. 13, 1217-1226 (2006).
46. Berkers, C. R. et al. Profiling proteasome activity in tissue with fluorescent probes. Mol. Pharm. [in the press].
47. Verdoes, M. et al. Mixing of peptides and electrophilic traps gives rise to potent, broad-spectrum proteasome inhibitors. Org. Biomol. Chem. 5, 1416-1426 (2007).
48. Altun, M. et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res. 65, 7896-7901 (2005).
49. Kraus, M. et al. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 21, 84-92 (2007).
50. Wilkinson, K. D., Cox, M. J., Mayer, A. N. & Frey, T. Synthesis and characterization of ubiquitin ethyl ester, a new substrate for ubiquitin carboxyl-terminal hydrolase. Biochemistry 25, 6644-6649 (1986).
51. Dang, L. C., Melandri, F. D. & Stein, R. L. Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes. Biochemistry 37, 1868-1879 (1998).
52. Hershko, A. & Rose, I. A. Ubiquitin-aldehyde: a general inhibitor of ubiquitin-recycling processes. Proc. Natl Acad. Sci. USA 84, 1829-1833 (1987).
53. Pickart, C. M. & Rose, I. A. Mechanism of ubiquitin carboxyl-terminal hydrolase. Borohydride and hydroxylamine inactivate in the presence of ubiquitin. J. Biol. Chem. 261, 10210-10217 (1986).
54. Lam, Y. A., Xu, W., DeMartino, G. N. & Cohen, R. E. Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome. Nature 385, 737-740 (1997).
55. Borodovsky, A. et al. A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J. 20, 5187-5196 (2001).
56. Muralidharan, V. & Muir, T. W. Protein ligation: an enabling technology for the biophysical analysis of proteins. Nature Methods 3, 429-438 (2006).
57. Borodovsky, A. et al. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 9, 1149-1159 (2002).
58. Denison, C., Kirkpatrick, D. S. & Gygi, S. P. Proteomic insights into ubiquitin and ubiquitin-like proteins. Curr. Opin. Chem. Biol. 9, 69-75 (2005).
59. Kirkpatrick, D. S., Denison, C. & Gygi, S. P. Weighing in on ubiquitin: the expanding role of mass-spectrometry-based proteomics. Nature Cell Biol. 7, 750-757 (2005).
60. Hemelaar, J. et al. Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol. Cell Biol. 24, 84-95 (2004).
61. Kang, S. H. et al. Two novel ubiquitin-fold modifier 1 (Ufm1)-specific proteases, UfSP1 and UfSP2. J. Biol. Chem. 282, 5256-5262 (2006).
62. Evans, P. C. et al. Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem. J. 378, 727-734 (2004).
63. Rolen, U. et al. Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol. Carcinog. 45, 260-269 (2006).
64. Ovaa, H. et al. Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc. Natl Acad. Sci. USA 101, 2253-2258 (2004).
65. Kattenhorn, L. M., Korbel, G. A., Kessler, B. M., Spooner, E. & Ploegh, H. L. A deubiquitinating enzyme encoded by HSV-1 belongs to a family of cysteine proteases that is conserved across the family Herpesviridae. Mol. Cell 19, 547-557 (2005).
66. Wang, J., Loveland, A. N., Kattenhorn, L. M., Ploegh, H. L. & Gibson, W. High-molecular-weight protein (pUL48) of human cytomegalovirus is a competent deubiquitinating protease: mutant viruses altered in its active-site cysteine or histidine are viable. J. Virol. 80, 6003-6012 (2006).
67. Misaghi, S. et al. Chlamydia trachomatis-derived deubiquitinating enzymes in mammalian cells during infection. Mol. Microbiol. 61, 142-150 (2006).
68. Artavanis-Tsakonas, K. et al. Identification by functional proteomics of a deubiquitinating/deNeddylating enzyme in Plasmodium falciparum. Mol. Microbiol. 61, 1187-1195 (2006).
69. Catic, A., Misaghi, S., Korbel, G. A. & Ploegh, H. L. ElaD, a deubiquitinating protease expressed by E. coli. PLoS. ONE 2, e381 (2007).
70. Mukherjee, S. et al. Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science 312, 1211-1214 (2006).
71. Hu, M. et al. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111, 1041-1054 (2002).
72. Renatus, M. et al. Structural basis of ubiquitin recognition by the deubiquitinating protease USP2. Structure 14, 1293-1302 (2006).
73. Hu, M. et al. Structure and mechanisms of the proteasome- associated deubiquitinating enzyme USP14. EMBO J. 24, 3747-3756 (2005).
74. Mullally, J. E., Moos, P. J., Edes, K. & Fitzpatrick, F. A. Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J. Biol. Chem. 276, 30366-30373 (2001).
75. Liu, Y. et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol. 10, 837-846 (2003).
76. Graner, E. et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5, 253-261 (2004).
77. Priolo, C. et al. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res. 66, 8625-8632 (2006).
78. Popov, N. et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nature Cell Biol. 9, 765-774.
79. Lim, H. S., Archer, C. T. & Kodadek, T. Identification of a peptoid inhibitor of the proteasome 19S regulatory particle. J. Am. Chem. Soc. 129, 7750-7751 (2007).
80. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
81. Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nature Med. 10, 1321-1328 (2004).
82. Krajewski, M., Ozdowy, P., D'Silva, L., Rothweiler, U. & Holak, T. A. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nature Med. 11, 1135-1136 (2005).
83. Concannon, C. G. et al. Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway. Oncogene 26, 1681-1692 (2007).
84. Nair, V. D., McNaught, K. S., Gonzalez-Maeso, J., Sealfon, S. C. & Olanow, C. W. p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J. Biol. Chem. 281, 39550-39560 (2006).
85. Hideshima, T. et al. NF-κ B as a therapeutic target in multiple myeloma. J. Biol. Chem. 277, 16639-16647 (2002).
86. Miyoshi, Y. et al. High expression of ubiquitin carboxyterminal hydrolase-L1 and-L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Sci. 97, 523-529 (2006).
87. Nijman, S. M. et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 17, 331-339 (2005).
88. Huang, T. T. et al. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nature Cell Biol. 8, 339-347 (2006).
89. Stevenson, L. F. et al. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J. 26, 976-986 (2007).
90. Oishi, K. et al. Genome-wide expression analysis of mouse liver reveals CLOCK-regulated circadian output genes. J. Biol. Chem. 278, 41519-41527 (2003).
91. Gray, D. A. et al. Elevated expression of Unph, a protooncogene at 3p21. 3, in human lung tumors. Oncogene 10, 2179-2183 (1995).
92. Gilchrist, C. A. & Baker, R. T. Characterization of the ubiquitin-specific protease activity of the mouse/human Unp/Unph oncoprotein. Biochim. Biophys. Acta 1481, 297-309 (2000).
93. Ghbeish, N. et al. The dual role of ultraspiracle, the Drosophila retinoid X receptor, in the ecdysone response. Proc. Natl Acad. Sci. USA 98, 3867-3872 (2001).
94. Blanchette, P., Gilchrist, C. A., Baker, R. T. & Gray, D. A. Association of UNP, a ubiquitin-specific protease, with the pocket proteins pRb, p107 and p130. Oncogene 20, 5533-5537 (2001).
95. Gupta, K., Copeland, N. G., Gilbert, D. J., Jenkins, N. A. & Gray, D. A. Unp, a mouse gene related to the tre oncogene. Oncogene 8, 2307-2310 (1993).
96. Gilchrist, C. A., Gray, D. A. & Baker, R. T. A ubiquitinspecific protease that efficiently cleaves the ubiquitinproline bond. J. Biol. Chem. 272, 32280-32285 (1997).
97. Oliveira, A. M. et al. Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. Oncogene 24, 3419-3426 (2005).
98. Oliveira, A. M. et al. USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res. 64, 1920-1923 (2004).
99. Martinu, L. et al. The TBC (Tre-2/Bub2/Cdc16) domain protein TRE17 regulates plasma membrane-endosomal trafficking through activation of Arf6. Mol. Cell Biol. 24, 9752-9762 (2004).
100. Masuda-Robens, J. M., Kutney, S. N., Qi, H. & Chou, M. M. The TRE17 oncogene encodes a component of a novel effector pathway for Rho GTPases Cdc42 and Rac1 and stimulates actin remodeling. Mol. Cell Biol. 23, 2151-2161 (2003).
101. Menin, C. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J. Natl Cancer Inst. 98, 285-288 (2006).
102. Masuya, D. et al. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways. J. Pathol. 208, 724-732 (2006).
103. Li, M. et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416, 648-653 (2002).
104. Cummins, J. M. et al. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 428, 1 (2004).
105. Meulmeester, E. et al. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol. Cell 18, 565-576 (2005).
106. Taya, S., Yamamoto, T., Kanai-Azuma, M., Wood, S. A. & Kaibuchi, K. The deubiquitinating enzyme Fam interacts with and stabilizes beta-catenin. Genes Cells 4, 757-767 (1999).
107. Deng, S. et al. Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast Cancer Res. Treat. 104, 21-30.
108. Murray, R. Z., Jolly, L. A. & Wood, S. A. The FAM deubiquitylating enzyme localizes to multiple points of protein trafficking in epithelia, where it associates with E-cadherin and beta-catenin. Mol. Biol. Cell 15, 1591-1599 (2004).
109. Grunda, J. M. et al. Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). J. Neurooncol. 80, 261-274 (2006).
110. Faus, H., Meyer, H. A., Huber, M., Bahr, I. & Haendler, B. The ubiquitin-specific protease USP10 modulates androgen receptor function. Mol. Cell Endocrinol. 245, 138-146 (2005).
111. Shinji, S. et al. Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. Oncol. Rep. 15, 539-543 (2006).
112. Baker, R. T., Wang, X. W., Woollatt, E., White, J. A. & Sutherland, G. R. Identification, functional characterization, and chromosomal localization of USP15, a novel human ubiquitin-specific protease related to the UNP oncoprotein, and a systematic nomenclature for human ubiquitin-specific proteases. Genomics 59, 264-274 (1999).
113. Schweitzer, K., Bozko, P. M., Dubiel, W. & Naumann, M. CSN controls NF-κB by deubiquitinylation of IκBα. EMBO J. 26, 1532-1541 (2007).
114. De Pitta, C. et al. A leukemia-enriched cDNA microarray platform identifies new transcripts with relevance to the biology of pediatric acute lymphoblastic leukemia. Haematologica 90, 890-898 (2005).
115. Li, Z., Wang, D., Messing, E. M. & Wu, G. VHL proteininteracting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. EMBO Rep. 6, 373-378 (2005).
116. Paulsson, K. et al. A novel and cytogenetically cryptic t(7;21)(p22;q22) in acute myeloid leukemia results in fusion of RUNX1 with the ubiquitin-specific protease gene USP42. Leukemia 20, 224-229 (2006).
117. Bignell, G. R. et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nature Genet. 25, 160-165 (2000).
118. Young, A. L. et al. CYLD mutations underlie Brooke-Spiegler, familial cylindromatosis, and multiple familial trichoepithelioma syndromes. Clin. Genet. 70, 246-249 (2006).
119. Massoumi, R., Chmielarska, K., Hennecke, K., Pfeifer, A. & Fassler, R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-κB signaling. Cell 125, 665-677 (2006).
120. Brummelkamp, T. R., Nijman, S. M., Dirac, A. M. & Bernards, R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424, 797-801 (2003).
121. Trompouki, E. et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 424, 793-796 (2003).
122. Jono, H. et al. NF-κB is essential for induction of CYLD, the negative regulator of NF-κB: evidence for a novel inducible autoregulatory feedback pathway. J. Biol. Chem. 279, 36171-36174 (2004).
123. Kovalenko, A. et al. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 424, 801-805 (2003).
124. Regamey, A. et al. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor κB activation by tumor necrosis factor. J. Exp. Med. 198, 1959-1964 (2003).
125. Wertz, I. E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430, 694-699 (2004).
126. Vendrell, J. A. et al. A20/TNFAIP3, a new estrogenregulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene 12 February 2007 (Epub ahead of print).
127. Jensen, D. E. et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16, 1097-1112 (1998).
128. Sobhian, B. et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 316, 1198-1202 (2007).
129. Dong, Y. et al. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol. Cell 12, 1087-1099 (2003).
130. Chen, X., Arciero, C. A., Wang, C., Broccoli, D. & Godwin, A. K. BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation. Cancer Res. 66, 5039-5046 (2006).